Lenalidomide-Associated ITP

  • Herold C
  • Gasparetto C
  • Arepally G
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.

Cite

CITATION STYLE

APA

Herold, C. I., Gasparetto, C., & Arepally, G. M. (2011). Lenalidomide-Associated ITP. Case Reports in Hematology, 2011, 1–4. https://doi.org/10.1155/2011/638020

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free